Sammour Yasser M, Anwaar Muhammad Faraz, Cabral-Amador Francisco, Garcia Jian, Aoun Joe, Kazmi Sana, Faza Nadeen, Little Stephen H, Reardon Michael J, Kleiman Neal S, Goel Sachin S
Department of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Heart Int. 2024 Dec 18;18(2):24-36. doi: 10.17925/HI.2024.18.2.4. eCollection 2024.
Tricuspid regurgitation (TR) is a common valvular heart disease that is associated with increased morbidity and mortality. Traditional surgical interventions, though definitive, carry considerable complexities and risks, especially for high-risk patients, with in-hospital mortality rates of ˜9%. This resulted in the undertreatment of many patients with TR, creating a substantial unmet need. This has stimulated the development of transcatheter techniques, such as transcatheter tricuspid valve replacement, tricuspid edge-to-edge repair, tricuspid annuloplasty, caval valve implantation and many others, which offer less-i nvasive alternatives with promising early results and sustained benefits. This review provides a contemporary outlook on different transcatheter tricuspid valve interventions in patients with severe TR and assesses the existing clinical data regarding the safety and effectiveness of these devices in a rapidly expanding space.
三尖瓣反流（TR）是一种常见的心脏瓣膜疾病，与发病率和死亡率的增加相关。传统的外科手术干预虽然具有决定性作用，但存在相当大的复杂性和风险，尤其是对于高危患者，其院内死亡率约为9%。这导致许多TR患者治疗不足，产生了大量未满足的需求。这刺激了经导管技术的发展，如经导管三尖瓣置换术、三尖瓣缘对缘修复术、三尖瓣环成形术、腔静脉瓣膜植入术等，这些技术提供了侵入性较小的替代方案，早期结果令人鼓舞且益处持续。本综述对重度TR患者的不同经导管三尖瓣干预措施提供了当代观点，并评估了在这个迅速扩展的领域中这些装置安全性和有效性的现有临床数据。
